Related references
Note: Only part of the references are listed.Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease
Shi-Dong Chen et al.
TRANSLATIONAL PSYCHIATRY (2021)
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Shorena Janelidze et al.
NATURE MEDICINE (2020)
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
Elisabeth H. Thijssen et al.
NATURE MEDICINE (2020)
Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography
Pierre-Francois Meyer et al.
JAMA NEUROLOGY (2020)
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling data from four cohorts
Thomas K. Karikari et al.
LANCET NEUROLOGY (2020)
A beta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease
Niklas Mattsson-Carlgren et al.
SCIENCE ADVANCES (2020)
Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
James D. Doecke et al.
NEUROLOGY (2020)
Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
Xue-Ning Shen et al.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2020)
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
Andrea Vergallo et al.
ALZHEIMERS & DEMENTIA (2019)
Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia
Clifford R. Jack et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Suzanne E. Schindler et al.
NEUROLOGY (2019)
Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study
Jin-Tai Yu et al.
ALZHEIMERS & DEMENTIA (2019)
Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a gray zone?
Kevin McRae-McKee et al.
ALZHEIMERS & DEMENTIA (2019)
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
Sebastian Palmqvist et al.
EMBO MOLECULAR MEDICINE (2019)
Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease
Jong-Chan Park et al.
BRAIN (2019)
BLOOD-BRAIN BARRIER: FROM PHYSIOLOGY TO DISEASE AND BACK
Melanie D. Sweeney et al.
PHYSIOLOGICAL REVIEWS (2019)
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study
Virginia Perez-Grijalba et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
Silvia Fossati et al.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2019)
Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography
Michelle M. Mielke et al.
ALZHEIMERS & DEMENTIA (2018)
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
Oskar Hansson et al.
ALZHEIMERS & DEMENTIA (2018)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease
Che-Chuan Yang et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes
Chin-Hsien Lin et al.
FRONTIERS IN AGING NEUROSCIENCE (2018)
Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome
Harutsugu Tatebe et al.
MOLECULAR NEURODEGENERATION (2017)
Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic
Sid E. O'Bryant et al.
ALZHEIMERS & DEMENTIA (2017)
Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid
Tobias Bittner et al.
ALZHEIMERS & DEMENTIA (2016)
In Vivo Cortical Spreading Pattern of Tau and Amyloid in the Alzheimer Disease Spectrum
Hanna Cho et al.
ANNALS OF NEUROLOGY (2016)
Establishment and Dysfunction of the Blood-Brain Barrier
Zhen Zhao et al.
CELL (2015)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann et al.
ALZHEIMERS & DEMENTIA (2011)
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
Susan M. Landau et al.
NEUROBIOLOGY OF AGING (2011)
Comparing predictors of conversion and decline in mild cognitive impairment
S. M. Landau et al.
NEUROLOGY (2010)
Share Paper
